Korean biotech firm tees up W205bn listing
SillaJen Biotherapeutics is planning to go public with an eye to raise W205bn ($179.4m), according to a termsheet seen by GlobalCapital Asia.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts